10-K: Cencora Reports Strong FY25 Growth, Strategic Acquisitions

Cencora, Inc. announced robust financial results for fiscal year 2025, driven by significant revenue growth in U.S. Healthcare Solutions and strategic acquisitions, despite a goodwill impairment charge.

Summary

• Revenue increased by $27.4 billion, or 9.3%, to $321.3 billion in fiscal 2025, with U.S. Healthcare Solutions growing 9.7% and International Healthcare Solutions growing 6.1%.
• U.S. Healthcare Solutions revenue growth was largely driven by unit volume, including a $7.7 billion (26.9%) increase in sales of products labeled for diabetes and/or weight loss in the GLP-1 class.
• Gross profit increased by $1,568.5 million, or 15.8%, to $11.5 billion, primarily due to increased gross profit in the U.S. Healthcare Solutions segment and larger gains from antitrust litigation settlements.
• Total operating expenses increased by $1,115.2 million, or 14.4%, to $8.8 billion, mainly due to the January 2025 acquisition of Retina Consultants of America (RCA), a larger goodwill impairment, and increased acquisition-related deal and integration expenses.
• A goodwill impairment of $723.9 million was recorded for the PharmaLex reporting unit in fiscal 2025 due to weakening demand in the life sciences industry.
• Total segment operating income increased by $574.7 million, or 15.8%, to $4.2 billion.
• Net income attributable to Cencora, Inc. was $1,554.169 million ($8.02 basic EPS) in fiscal 2025, up from $1,509.120 million ($7.60 basic EPS) in fiscal 2024.
• The effective tax rate increased to 30.6% in fiscal 2025 from 24.2% in fiscal 2024, primarily due to non-deductible impairments and U.S. state income taxes.
• Cash provided by operating activities increased by $390.4 million to $3.9 billion in fiscal 2025.
• The company acquired an 85% interest in Retina Consultants of America (RCA) on January 2, 2025, for $4,042.0 million in cash, plus contingent consideration and settlement of a pre-existing receivable.
• The accrued litigation liability for opioid settlements was $4.3 billion as of September 30, 2025, with $416.0 million expected to be paid prior to September 30, 2026.
• The Board of Directors increased the quarterly dividend by 9% to $0.60 per share, payable on December 1, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue and profit growth, successful strategic acquisitions, and increased shareholder returns through dividends and share repurchases. However, a significant goodwill impairment charge for PharmaLex, a decrease in International Healthcare Solutions operating income, and rising interest expenses temper the overall positive sentiment. Ongoing, complex opioid litigation and increasing regulatory scrutiny also present notable headwinds.

Positives

• Strong revenue growth of 9.3% to $321.3 billion in fiscal 2025, demonstrating overall market growth.
• U.S. Healthcare Solutions revenue grew 9.7%, significantly boosted by increased sales of specialty products and GLP-1 class products, which rose by $7.7 billion or 26.9%.
• Gross profit increased by 15.8% to $11.5 billion, outpacing revenue growth, with U.S. Healthcare Solutions gross profit up 23.1%.
• Gains from antitrust litigation settlements increased to $236.4 million in fiscal 2025 from $170.9 million in fiscal 2024.
• Total segment operating income increased by 15.8% to $4.2 billion, indicating improved operational efficiency.
• Net income attributable to Cencora, Inc. increased to $1.55 billion, and basic earnings per share rose to $8.02.
• Cash provided by operating activities increased by $390.4 million to $3.9 billion, reflecting strong cash generation.
• The acquisition of an 85% interest in Retina Consultants of America (RCA) for $4.04 billion in cash is expected to broaden relationships with community providers and strengthen leadership in specialty pharmaceuticals.
• The quarterly dividend was increased by 9% to $0.60 per share, signaling confidence in future financial performance and commitment to shareholder returns.
• The Multi-Currency Revolving Credit Facility was increased to $4.5 billion and its expiration extended to June 2030, enhancing liquidity and financial flexibility.
• The commercial paper program was increased to $4.5 billion, and the Receivables Securitization Facility was extended to June 2028 and increased to $1.5 billion, further strengthening financing capabilities.

Negatives

• A significant goodwill impairment charge of $723.9 million was recorded for the PharmaLex reporting unit in fiscal 2025 due to weakening demand in the life sciences industry.
• International Healthcare Solutions operating income decreased by $65.1 million, or 9.1%, from the prior fiscal year.
• The effective tax rate increased to 30.6% in fiscal 2025 from 24.2% in fiscal 2024, primarily due to non-deductible impairments and an increase in unrecognized tax benefits.
• Other loss (income), net included a $113.5 million impairment of an equity investment and a $35.5 million loss on the divestiture of non-core businesses.
• Interest expense, net increased by $134.6 million, or 85.7%, primarily due to new debt issuances to finance the RCA acquisition and for general corporate purposes.
• Increases in accounts receivable ($1.9 billion) and inventories ($1.3 billion) consumed cash from operations in fiscal 2025.
• The accrued litigation liability for opioid settlements remains substantial at $4.3 billion, with ongoing payments expected over 13 years.
• An oncology customer contract was terminated in June 2025 due to non-renewal, impacting future revenue.
• Ongoing legal proceedings related to opioid distribution, including a civil complaint from the Department of Justice, continue to pose legal and financial risks.
• A jury verdict in Maryland found a subsidiary liable for public nuisance, assessing approximately $274 million in compensatory damages (later reduced to $42.5 million for the subsidiary by the court, but subject to appeal/cross-appeal).

Risks

• Loss or renewal at less favorable terms of key customer or group purchasing organization relationships, as Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services 13% in fiscal 2025.
• Potential changes to the relationship with Walgreens and Boots under new ownership, including store closures, could adversely affect contractual arrangements and business results.
• Disruption in distribution or generic purchasing services arrangements with Walgreens or WBAD could adversely affect business and financial results.
• Acquisitions of or investments in businesses, such as RCA and OneOncology, may fail to achieve expected financial and operating performance, be difficult to integrate, or introduce new regulatory or compliance issues.
• Difficulties in managing and completing divestitures, potential ongoing exposure in divested businesses, or restrictions from re-entering applicable markets.
• Geopolitical and other risks associated with international operations in over 50 countries, including local law changes, economic conditions (e.g., Turkey's highly inflationary economy), currency volatility, and trade policies/tariffs.
• Fluctuations in foreign currency exchange rates could reduce revenues or increase costs when reported in U.S. dollars.
• Operational and logistical risks inherent in pharmaceutical distribution, including cold chain storage and shipping, which might not be fully covered by insurance.
• Industry-specific risks inherent to the healthcare industry, including distribution, administration, and consulting services, which may not be covered by insurance or indemnification obligations.
• Inability to successfully recruit, engage, develop, and retain qualified and experienced employees, including key executives, or potential disruptions from collective bargaining agreements.
• Loss or disruption of information systems, including from cyberattacks (e.g., ransomware, AI-driven attacks), could disrupt operations, lead to data loss, damage reputation, and increase costs.
• Manufacturer pricing changes, including those related to wholesale acquisition cost (WAC), price inflation/deflation, and government policy initiatives (e.g., Executive Order 14297, GLOBE/GUARD Models), could adversely impact results of operations.
• Competition and industry consolidation of both customers and suppliers may erode profit margins and negotiating power.
• Bankruptcy, insolvency, or other credit failure of a significant customer or supplier could have a material adverse effect on revenue, results of operations, financial position, and cash flows.
• Financial market volatility and disruption or a downgrade in credit ratings could adversely affect stock price and ability to access credit markets.
• Declining economic conditions, including interest rate fluctuations and inflation, could adversely affect customer purchases, revenue growth, and profitability.
• Increasing governmental efforts to regulate the pharmaceutical supply chain (e.g., DSCSA, FDA proposed rules, Falsified Medicines Directive, Critical Medicines Act, EU pharmaceutical package) may increase costs and reduce profitability.
• Legal, regulatory, and legislative changes with respect to coverage, reimbursement, pricing, and contracting (e.g., ACA, IRA, OBBBA, Medicare Part B/D changes, 340B program disputes) may adversely affect business and results of operations.
• Failure to comply with laws and regulations in respect of healthcare fraud and abuse could result in penalties or require significant changes to operations.
• Adverse outcomes from legal proceedings, including antitrust, commercial, data privacy, opioid lawsuits, and government investigations, could materially affect financial position, results of operations, and cash flows.
• Opioid-related legal proceedings and the Distributor Settlement Agreement could adversely impact cash flows or results of operations, including potential for excessive monetary verdicts and/or injunctive relief.
• Public concern over the abuse of medications could negatively affect business, including potential taxes or assessments on the sale or distribution of opioid medications.
• Tax legislation or challenges to tax positions could adversely affect results of operations and financial position.
• Violations of anti-bribery, anti-corruption, and/or international trade laws (e.g., FCPA, U.K. Bribery Act) could have a material adverse effect on business, financial position, and results of operations.
• Any actual or perceived failure to adequately protect proprietary business information or personal data (e.g., HIPAA, GDPR, PIPEDA, AI-related regulations) could result in claims of liability, damage reputation, or materially harm business.
• Third-party business partners are vulnerable to cybersecurity risks, and any cyber incident affecting them could significantly disrupt operations.
• Any actual or perceived failure to protect the company's reputation could have a material adverse effect on business and operations.
• Intellectual property rights may not provide meaningful commercial protection against unauthorized use or infringement claims.
• Adverse impacts from events outside of control, such as widespread public health issues, natural disasters, government policy changes, and political events.
• Goodwill or long-lived assets may become impaired, which may require recording a significant charge to earnings.
• Exclusive forum provisions in the amended and restated bylaws could limit stockholders' ability to choose their preferred judicial forum for disputes with the company or its directors, officers, or employees.

Future Outlook

Cencora expects future revenue growth to be influenced by industry trends, including drug utilization (e.g., GLP-1 products), new therapies, and generic/biosimilar availability, as well as economic conditions, currency exchange rates, competition, and regulatory changes. The company anticipates continuing quarterly cash dividends, subject to Board discretion. Approximately $900 million is projected for capital expenditures in fiscal 2026, focusing on distribution network expansion and technology initiatives. A new reporting structure, comprising U.S. Healthcare Solutions, International Healthcare Solutions, and Other, will be effective in the first quarter of fiscal 2026, with strategic alternatives being explored for businesses in the 'Other' segment. The $4.3 billion opioid litigation liability will be paid over 13 years, with no expected impact on dividend payments.

Management Comments

• Our business strategy is focused on the global pharmaceutical supply chain where we provide distribution and value-added services to healthcare providers... and pharmaceutical manufacturers to improve channel efficiencies and support positive patient outcomes.
• We are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy: Optimize and Grow U.S. Healthcare Solutions Businesses, Optimize and Grow Our International Healthcare Solutions Businesses, Acquisitions and Investments, Divestitures.
• We believe we have one of the lowest operating cost structures among pharmaceutical distributors.
• We continue to seek opportunities to achieve increased productivity and drive operating income gains as we invest in and continue to implement warehouse automation technology, adopt best practices in warehousing activities, and increase operating leverage by increasing volume per full-service distribution facility.
• We believe the acquisition of RCA allows us to broaden our relationships with community providers and to build on our leadership in specialty pharmaceuticals within our U.S. Healthcare Solutions reportable segment.
• We are deeply committed to diversion control efforts, have sophisticated systems to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in due diligence and ongoing monitoring of customers.
• We deny the allegations in the Complaint [DOJ civil complaint] and intend to defend itself vigorously in the litigation.
• We believe that maintaining and enhancing our reputation is critical to our ability to expand and retain our customer base, strategic partnerships and other key relationships.

Industry Context

The U.S. pharmaceutical market is projected to grow at a compound annual growth rate of approximately 8.4% from 2024 through 2029, driven by an aging population, the introduction of new pharmaceuticals (including biotechnology and gene therapy), and increased utilization of generic and biosimilar drugs. Generic and biosimilar pharmaceuticals, while having lower prices, historically offer greater gross profit margin opportunities and currently account for about 90% of U.S. prescription volume. The healthcare industry is experiencing increasing consolidation, leading to heightened competitive pressures. There are growing governmental efforts to regulate the pharmaceutical supply chain, with new laws and regulations (e.g., DSCSA, EU's Falsified Medicines Directive, Critical Medicines Act, EU pharmaceutical package) increasing compliance burdens and costs. Legal, regulatory, and legislative changes, such as those from the ACA, IRA, and OBBBA, are significantly impacting drug pricing, coverage, and reimbursement across federal programs like Medicare and Medicaid, as well as the 340B program. Public concern over opioid abuse continues to drive investigations, lawsuits, and legislative measures. Additionally, evolving regulatory frameworks for Artificial Intelligence (AI) are expected to impose new obligations and increase compliance costs.

Comparison to Industry Standards

• The company states it has one of the lowest operating cost structures among pharmaceutical distributors, indicating a competitive advantage in efficiency.
• The U.S. human health distribution businesses compete directly with industry giants like McKesson Corporation and Cardinal Health, Inc., as well as national generic and regional distributors.
• The Elevate Provider Network is noted as one of the largest managed care networks in the United States, suggesting a strong market position in connecting retail pharmacies to payor plans.
• The global specialty transportation and logistics provider for the biopharmaceutical industry faces competition from a variety of entities, including UPS Logistics.

Management Changes

Corporate Governance

Legal Proceedings

• The Distributor Settlement Agreement, resolving a substantial majority of opioid lawsuits from state and local governmental entities, became effective on April 2, 2022, with an accrued liability of $4.3 billion as of September 30, 2025, to be paid over 13 years.
• A proposed class action settlement agreement with third-party payors for opioid claims was entered on August 29, 2024, and received final approval on January 15, 2025 (effective September 9, 2025), with a $93.0 million litigation expense accrual.
• In the Maryland case filed by the Mayor and City Council of Baltimore, a jury found a subsidiary liable for public nuisance on November 12, 2024; the court later reduced the compensatory damages assessed against the subsidiary to $14.4 million and assessed $28 million for abatement measures (total $42.5 million), with appeals/cross-appeals filed in October 2025.
• A proposed class action settlement agreement with hospitals for opioid claims was entered on September 26, 2024, and received final approval on April 4, 2025, with a $120.9 million litigation expense accrual.
• The Department of Justice filed a civil complaint on December 29, 2022, against the Company and subsidiaries alleging violations of the Controlled Substances Act for negligent failure to report suspicious orders; the company denies allegations and is vigorously defending the litigation, with discovery ongoing until 2027.
• The Fourth Circuit Court of Appeals vacated a District Court judgment in favor of the company in an opioid case from West Virginia and remanded it for further proceedings on October 28, 2025.
• A shareholder derivative action alleging breach of fiduciary duty related to controlled substance diversion control programs was settled for $111.3 million (less $24.8 million in attorneys' fees) from insurance carriers, with court approval on November 13, 2025.
• An ongoing criminal investigation into MWI Veterinary Supply Co. by the U.S. Attorneys Office for the Western District of Virginia regarding compliance with regulatory requirements for animal health product shipments resulted in an agreement in principle to resolve in October 2024, with a $49.1 million litigation expense accrual.

Related Party Transactions

• Walgreens and Boots UK Ltd. (Boots) collectively accounted for approximately 25% of revenue and 38% of accounts receivable, net, in fiscal 2025, stemming from a U.S. distribution agreement, a generics purchasing services arrangement with WBAD, and an international distribution agreement with Boots.
• Evernorth Health Services, the company's second-largest customer, accounted for approximately 13% of revenue and 5% of accounts receivable as of September 30, 2025.
• The acquisition of Retina Consultants of America (RCA) included $694.4 million of contingent consideration related to equity units for certain RCA physicians and members of management who retained a 15% interest in RCA.
• The investment in OneOncology is a joint venture with TPG Inc., with put and call options governing the remaining interests in the joint venture.
• U.S. Bank is a lender and issuing bank in connection with the company's senior unsecured revolving credit facility and provides certain cash management services to the company and its subsidiaries.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue, operating income, EPS, and a 9% dividend increase, alongside an ongoing share repurchase program. Potential negative impact from goodwill impairment, increased debt, and ongoing, complex litigation risks. Exclusive forum provisions in bylaws could limit ability to choose judicial forum for disputes.
• Employees: Workforce reductions were noted under restructuring costs. The company invests in talent attraction, retention, and development programs, competitive compensation and benefits, and team member safety initiatives. Approximately 24% of global employees are covered by collective bargaining agreements.
• Customers: Benefit from improved pharmaceutical supply chain efficiency, value-added services, and expanded specialty product offerings (e.g., through the RCA acquisition). Potential negative impact from the loss of key contracts or changes in reimbursement policies.
• Suppliers: Relationships are generally good. Potential impact from manufacturer pricing changes and creditworthiness issues.
• Creditors: Increased debt levels due to acquisitions and general corporate purposes. Compliance with debt covenants is maintained. Credit ratings could be affected by financial market volatility or litigation liabilities.

Next Steps

• Continue to litigate and vigorously defend against ongoing opioid lawsuits and enforcement proceedings.
• Implement and maintain required changes to controlled substance anti-diversion programs under the Distributor Settlement Agreement.
• Expend additional resources to enhance security measures and investigate and remediate information security vulnerabilities.
• Continue to invest in advanced information systems and automated warehouse technology.
• Spend approximately $900 million on capital expenditures during fiscal 2026, focusing on distribution network expansion/enhancement and various technology initiatives.
• Evaluate the impact of adopting new accounting guidance (ASU 2023-09 and ASU 2024-03).
• Explore strategic alternatives for businesses in the 'Other' segment (MWI Animal Health, Profarma, U.S. Consulting Services, and other PharmaLex components) starting in fiscal 2026.
• Monitor manufacturers' chosen methodology for IRA price access compliance by December 2, 2025.
• Continue to pay quarterly cash dividends in the future, subject to Board discretion.

Key Dates

Recommendation

Cencora demonstrates strong operational performance with significant revenue and operating income growth, particularly in its U.S. Healthcare Solutions segment, driven by strategic acquisitions like RCA and high-growth products like GLP-1s. The increased dividend and ongoing share repurchase program signal confidence in future cash flows. However, the substantial goodwill impairment related to PharmaLex and the decrease in International Healthcare Solutions operating income highlight integration and market challenges. The company also faces considerable, unpredictable risks from ongoing opioid litigation, increasing regulatory scrutiny, and a rising debt load from recent financing activities. While the core business is robust, these headwinds and uncertainties warrant a cautious 'Hold' stance for investors, suggesting monitoring of litigation outcomes, integration success, and debt management.

Keywords

Pharmaceutical distribution, Healthcare solutions, Specialty pharmaceuticals, GLP-1, Acquisitions, Corporate governance, SEC filing, 10-K, Financial performance, Risk management, Opioid litigation, Supply chain, Cencora, COR, Debt securities, Senior notes, NYSE, Common stock, Dividends, Share repurchase, Cybersecurity, AI, Regulatory compliance, International operations, M&A, Financial reporting